Akero
0 followers
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being eva... Read more
Org chart
Andrew Cheng
President & CEO
Andrew Cheng
Collapse
Jonathan Young
COO & Co Founder
Tim Rolph
Chief Scientific Officer & Co-Founder
William White
CFO & Head of Corporate Development
Catriona Yale
Chief Development Officer
Dominick Villani
VP & Quality
Brittany de Temple
VP of Development Operations
Libette Luce
VP of Regulatory Affairs
Patrick Lamy
SVP, Commercial Strategy
Kitty Yale
EVP And Chief Development Officer
David West
Vice President Legal
